610 related articles for article (PubMed ID: 36427418)
21. Prospective Study of a Modified Post-Transplantation Cyclophosphamide Regimen for Severe Aplastic Anemia Patients with HLA-Haploidentical Transplantation.
Wu L; Zhou M; Li Y; Chen X; Mo W; Wang C; Xu S; Zhou W; Deng T; Zhou R; Pan S; Wang S; Zhang Y
Transplant Cell Ther; 2023 Jul; 29(7):463.e1-463.e7. PubMed ID: 37098408
[TBL] [Abstract][Full Text] [Related]
22. Posttransplantation cyclophosphamide improves transplantation outcomes in patients with AML/MDS who are treated with checkpoint inhibitors.
Oran B; Garcia-Manero G; Saliba RM; Alfayez M; Al-Atrash G; Ciurea SO; Jabbour EJ; Mehta RS; Popat UR; Ravandi F; Alousi AM; Kadia TM; Konopleva M; DiNardo CD; Rezvani K; Shpall EJ; Sharma P; Kantarjian HM; Champlin RE; Daver N
Cancer; 2020 May; 126(10):2193-2205. PubMed ID: 32125707
[TBL] [Abstract][Full Text] [Related]
23. Lower dose of ATG combined with basiliximab for haploidentical hematopoietic stem cell transplantation is associated with effective control of GVHD and less CMV viremia.
Huang Z; Yan H; Teng Y; Shi W; Xia L
Front Immunol; 2022; 13():1017850. PubMed ID: 36458000
[TBL] [Abstract][Full Text] [Related]
24. Posttransplant cyclophosphamide versus antithymocyte globulin in patients with acute lymphoblastic leukemia treated with allogeneic hematopoietic cell transplantation from matched unrelated donors: A study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.
Giebel S; Labopin M; Salmenniemi U; Socié G; Bondarenko S; Blaise D; Kröger N; Vydra J; Grassi A; Bonifazi F; Czerw T; Anagnostopoulos A; Lioure B; Ruggeri A; Savani B; Spyridonidis A; Sanz J; Peric Z; Nagler A; Ciceri F; Mohty M
Cancer; 2023 Dec; 129(23):3735-3745. PubMed ID: 37658621
[TBL] [Abstract][Full Text] [Related]
25. Post-transplant cyclophosphamide versus anti-thymocyte globulin for graft-versus-host disease prevention in haploidentical transplantation for adult acute lymphoblastic leukemia.
Nagler A; Kanate AS; Labopin M; Ciceri F; Angelucci E; Koc Y; Gülbas Z; Arcese W; Tischer J; Pioltelli P; Ozdogu H; Afanasyev B; Wu D; Arat M; Peric Z; Giebel S; Savani B; Mohty M
Haematologica; 2021 Jun; 106(6):1591-1598. PubMed ID: 32354866
[TBL] [Abstract][Full Text] [Related]
26. Post-transplant Cyclophosphamide Versus Thymoglobulin in HLA-Mismatched Unrelated Donor Transplant for Acute Myelogenous Leukemia and Myelodysplastic Syndrome.
Modi D; Kondrat K; Kim S; Deol A; Ayash L; Ratanatharathorn V; Uberti JP
Transplant Cell Ther; 2021 Sep; 27(9):760-767. PubMed ID: 34174469
[TBL] [Abstract][Full Text] [Related]
27. Post-transplant cyclophosphamide versus antithymocyte globulin in allogeneic hematopoietic cell transplantation: a meta-analysis.
Gao F; Zhang J; Hu J; Lin L; Xu Y
Ann Hematol; 2021 Feb; 100(2):529-540. PubMed ID: 33420575
[TBL] [Abstract][Full Text] [Related]
28. [The impact of donor-to-recipient gender compatibility on outcomes of haploid hematopoietic stem cell transplantation in patients with hematological malignancies].
Hu SS; Wu YB; Zhu PP; Shi JM; Yu J; Zhao YM; Lai XY; Liu LZ; Fu HR; Huang H; Luo Y
Zhonghua Xue Ye Xue Za Zhi; 2022 Dec; 43(12):992-1002. PubMed ID: 36709104
[No Abstract] [Full Text] [Related]
29. Post-transplant cyclophosphamide versus anti-thymocyte globulin after reduced intensity peripheral blood allogeneic cell transplantation in recipients of matched sibling or 10/10 HLA matched unrelated donors: final analysis of a randomized, open-label, multicenter, phase 2 trial.
Brissot E; Labopin M; Labussière H; Fossard G; Chevallier P; Guillaume T; Yakoub-Agha I; Srour M; Bulabois CE; Huynh A; Chantepie S; Menard AL; Rubio MT; Ceballos P; Dulery R; Furst S; Malard F; Blaise D; Mohty M
Blood Cancer J; 2024 Feb; 14(1):31. PubMed ID: 38374026
[TBL] [Abstract][Full Text] [Related]
30. Characteristics of Graft-Versus-Host Disease (GvHD) After Post-Transplantation Cyclophosphamide Versus Conventional GvHD Prophylaxis.
Saliba RM; Alousi AM; Pidala J; Arora M; Spellman SR; Hemmer MT; Wang T; Abboud C; Ahmed S; Antin JH; Beitinjaneh A; Buchbinder D; Byrne M; Cahn JY; Choe H; Hanna R; Hematti P; Kamble RT; Kitko CL; Laughlin M; Lekakis L; MacMillan ML; Martino R; Mehta PA; Nishihori T; Patel SS; Perales MA; Rangarajan HG; Ringdén O; Rosenthal J; Savani BN; Schultz KR; Seo S; Teshima T; van der Poel M; Verdonck LF; Weisdorf D; Wirk B; Yared JA; Schriber J; Champlin RE; Ciurea SO
Transplant Cell Ther; 2022 Oct; 28(10):681-693. PubMed ID: 35853610
[TBL] [Abstract][Full Text] [Related]
31. Reduced Cytokine Release Syndrome and Improved Outcomes with Earlier Immunosuppressive Therapy in Haploidentical Stem Cell Transplantation.
Tang J; Jensen RR; Bryan B; Hoda D; Hunter BD
Transplant Cell Ther; 2024 Apr; 30(4):438.e1-438.e11. PubMed ID: 38281591
[TBL] [Abstract][Full Text] [Related]
32. HLA-Haploidentical Peripheral Blood Stem Cell Transplantation with Post-Transplantation Cyclophosphamide versus HLA-Matched Unrelated Donor Transplantation for Myelodysplastic Syndrome.
Nakaya Y; Koh H; Konuma T; Shimomura Y; Ishiyama K; Itonaga H; Hino M; Doki N; Nishida T; Ohigashi H; Matsuoka KI; Kanda Y; Maruyama Y; Sawa M; Eto T; Hiramoto N; Fukuda T; Atsuta Y; Nakamae H
Transplant Cell Ther; 2024 Mar; 30(3):316.e1-316.e12. PubMed ID: 38108263
[TBL] [Abstract][Full Text] [Related]
33. Post-Transplantation Cyclophosphamide-Based Haploidentical versus Matched Unrelated Donor Peripheral Blood Hematopoietic Stem Cell Transplantation Using Myeloablative Targeted Busulfan-Based Conditioning for Pediatric Acute Leukemia.
Hong KT; Park HJ; Kim BK; An HY; Choi JY; Kang HJ
Transplant Cell Ther; 2022 Apr; 28(4):195.e1-195.e7. PubMed ID: 35021131
[TBL] [Abstract][Full Text] [Related]
34. Graft-versus-Host Disease Prophylaxis in Unrelated Peripheral Blood Stem Cell Transplantation with Post-Transplantation Cyclophosphamide, Tacrolimus, and Mycophenolate Mofetil.
Moiseev IS; Pirogova OV; Alyanski AL; Babenko EV; Gindina TL; Darskaya EI; Slesarchuk OA; Bondarenko SN; Afanasyev BV
Biol Blood Marrow Transplant; 2016 Jun; 22(6):1037-1042. PubMed ID: 26970381
[TBL] [Abstract][Full Text] [Related]
35. Less Is More: Superior Graft-versus-Host Disease-Free/Relapse-Free Survival with Reduced-Intensity Conditioning and Dual T Cell Depletion in Acute Myelogenous Leukemia.
Salas MQ; Chen S; Lam W; Pasic I; Gerbitz A; Michelis FV; Kim DDH; Al-Shaibani Z; Lipton JH; Mattsson J; Kumar R; Viswabandya A; Law AD
Biol Blood Marrow Transplant; 2020 Aug; 26(8):1511-1519. PubMed ID: 32422253
[TBL] [Abstract][Full Text] [Related]
36. Should anti-thymocyte globulin be added in post-transplant cyclophosphamide based matched unrelated donor peripheral blood stem cell transplantation for acute myeloid leukemia? A study on behalf of the Acute Leukemia Working Party of the EBMT.
Spyridonidis A; Labopin M; Brissot E; Moiseev I; Cornelissen J; Choi G; Ciceri F; Vydra J; Reményi P; Rovira M; Meijer E; Labussière-Wallet H; Blaise D; van Gorkom G; Kröger N; Koc Y; Giebel S; Bazarbachi A; Savani B; Nagler A; Mohty M
Bone Marrow Transplant; 2022 Dec; 57(12):1774-1780. PubMed ID: 36071114
[TBL] [Abstract][Full Text] [Related]
37. Post-transplantation cyclophosphamide reduces the incidence of acute graft-versus-host disease in patients with acute myeloid leukemia/myelodysplastic syndromes who receive immune checkpoint inhibitors after allogeneic hematopoietic stem cell transplantation.
Saberian C; Abdel-Wahab N; Abudayyeh A; Rafei H; Joseph J; Rondon G; Whited L; Gruschkus S; Fa'ak F; Daher M; Knape C; Safa H; Shoukier M; Suarez-Almazor ME; Marcotulli M; Ludford K; Gulbis AM; Konopleva M; Ohanian M; Ravandi F; Garcia-Manero G; Oran B; Popat UR; Mehta R; Alousi AM; Daver N; Champlin R; Diab A; Al-Atrash G
J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33637601
[TBL] [Abstract][Full Text] [Related]
38. Reduced intensity allogeneic stem cell transplant with anti-thymocyte globulin and post-transplant cyclophosphamide in acute myeloid leukemia.
Salas MQ; Prem S; Atenafu EG; Law AD; Lam W; Al-Shaibani Z; Loach D; Kim DDH; Michelis FV; Lipton JH; Kumar R; Mattsson J; Viswabandya A
Eur J Haematol; 2019 Nov; 103(5):510-518. PubMed ID: 31449699
[TBL] [Abstract][Full Text] [Related]
39. Busulfan dose intensity and outcomes in reduced-intensity allogeneic peripheral blood stem cell transplantation for myelodysplastic syndrome or acute myeloid leukemia.
Chen YB; Coughlin E; Kennedy KF; Alyea EP; Armand P; Attar EC; Ballen KK; Cutler C; Dey BR; Koreth J; McAfee SL; Spitzer TR; Antin JH; Soiffer RJ; Ho VT
Biol Blood Marrow Transplant; 2013 Jun; 19(6):981-7. PubMed ID: 23562738
[TBL] [Abstract][Full Text] [Related]
40. Low-dose anti-thymocyte globulin plus low-dose post-transplant cyclophosphamide-based regimen for prevention of graft-versus-host disease after haploidentical peripheral blood stem cell transplants: a large sample, long-term follow-up retrospective study.
Li X; Yang J; Cai Y; Huang C; Xu X; Qiu H; Niu J; Zhou K; Zhang Y; Xia X; Wei Y; Shen C; Tong Y; Dong B; Wan L; Song X
Front Immunol; 2023; 14():1252879. PubMed ID: 37954615
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
